Loading ...
According to an article just published in Business Week magazine, Pfizer – makers of Rogaine, are busy testing two potential hair loss drugs.
One of them was originally developed to treat asthma patients because it relaxes smooth muscle cells in blood vessels such as those found in lung airways, allowing patients to breathe.
“We found the compound was not well-suited [to treating] this disease, but we are now exploring its potential in hair loss,” said Pfizer spokesman Stephen Lederer in an e-mail to Business Week.
He added that scientists still don’t fully understand why relaxing certain blood vessels leads to hair growth, though this appears to be the same mechanism exploited by Rogaine.
The article also discusses the recent cancellation of the Curis hair loss trial due to safety concerns. On May 9, Procter & Gamble, which had partnered with Cambridge (Mass.)-based Curis to develop the new Curis hair loss product, pulled out of the deal citing unspecified safety issues in early trials.
The article is worth reading and shows that hair loss is still of interest to pharmaceutical companies despite some people’s misconceptions, and there is always ongoing research into new hair loss treatments.
Source: http://www.businessweek.com/bwdaily/dnflash/content/jun2007/db20070615_535601.htm
(1 votes, average: 5 out of 5)
Loading ...